AstraZeneca has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. The purchase was valued at approximately $102 million and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.

Marc Dunoyer, chief financial officer, AstraZeneca, said, “Our decision to gain full control of AstraZeneca K.K. reinforces our focus on Japan as a key growth platform.”